# Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

> **NCT00389870** · PHASE3 · COMPLETED · sponsor: **University of Leeds** · enrollment: 1198 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** panitumumab
- **DRUG:** cyclosporine
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00389870
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1198 (ACTUAL)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389870, "Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00389870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*